GSK's albiglutide fails to match Victoza in its first Phase III trial
This article was originally published in Scrip
Executive Summary
A head-to-head Phase III study of GlaxoSmithKline's once-weekly experimental GLP-1 agonist albiglutide (Syncria) failed to show non-inferiority to Novo Nordisk's Victoza (liraglutide) in patients with type 2 diabetes.